Investment Thesis
Artiva Biotherapeutics is a pre-revenue biotech company with zero reported revenue and annual cash burn of approximately $21M, providing roughly one year of operational runway with current cash reserves. The company demonstrates significant cash outflows from operations (-$20.9M), deeply negative returns on equity (-26.8%) and assets (-22.2%), with no demonstrated commercialization progress or path to profitability.
Strengths
- Strong balance sheet with $87.8M stockholders' equity relative to $18.1M liabilities
- Excellent liquidity position with 8.16x current ratio and zero debt burden
- $21.0M cash reserve provides near-term operational funding
Risks
- Zero commercial revenue indicates clinical/development stage with no revenue-generating assets
- Operating cash burn of -$20.9M annually with limited cash runway of approximately one year
- Negative profitability metrics (ROE -26.8%, ROA -22.2%) with no near-term monetization visibility
Key Metrics to Watch
- Cash burn rate trend and actual runway duration
- Clinical development progress and regulatory milestone achievements
- Revenue inflection point or partnership announcements
Financial Metrics
Revenue
0.0
Net Income
-23.5M
EPS (Diluted)
$-0.95
Free Cash Flow
-21.2M
Total Assets
106.0M
Cash
21.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-26.8%
ROA
-22.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.16x
Quick Ratio
8.16x
Debt/Equity
0.00x
Debt/Assets
17.1%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:36:35.454330 |
Data as of: 2026-03-31 |
Powered by Claude AI